OV4071

OV4071 is an orally administered small molecule that acts as a direct activator of the potassium-chloride cotransporter 2 (KCC2). It is being developed by Ovid Therapeutics for the treatment of psychotic disorders and conditions associated with neural hyperexcitability. Preclinical studies have demonstrated strong anti-psychosis activity in animal models. The initial clinical focus for OV4071 is on psychosis associated with neuronal-synuclein diseases such as Parkinson’s disease and Lewy body dementia. The drug represents a first-in-class approach targeting KCC2 to modulate neuronal excitability, which may have broad therapeutic potential across various neuropsychiatric and neurological disorders[1][3][5][6].